Marksans Pharma Ltd. has announced its audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The company’s Board of Directors has recommended a final dividend of ₹0.90 per equity share. The financial results highlight the company’s performance over the past fiscal year, with detailed standalone and consolidated statements now available.
Marksans Pharma Announces Audited Financials and Dividend
Marksans Pharma Ltd. has officially released its audited standalone and consolidated financial results for the fiscal year that concluded on March 31, 2026. The company’s Board of Directors convened on May 26, 2026, to review and approve these results, along with the auditors’ reports. Following this approval, the Board has recommended a final dividend payout of ₹0.90 per equity share, representing 90% of the face value, for the financial year 2025-26. This dividend, if approved by the shareholders at the upcoming Annual General Meeting (AGM), is expected to be credited or dispatched within 30 days from the AGM date.
Key Financial Highlights
The standalone financial results for the year ended March 31, 2026, show a profit before tax of ₹3,915.43 million and a profit after tax of ₹3,006.98 million. Total comprehensive income stood at ₹3,017.39 million. The earnings per equity share (basic and diluted) were ₹6.64 and ₹6.63, respectively.
On a consolidated basis, the company reported a profit before tax of ₹5,605.55 million and a profit after tax of ₹4,200.64 million for the same period. The total comprehensive income for the group was ₹5,962.12 million. Consolidated earnings per equity share (basic and diluted) were ₹9.22.
Dividend Recommendation
The Board of Directors’ decision to recommend a final dividend of ₹0.90 per equity share underscores the company’s commitment to shareholder returns. This recommendation will be presented to the shareholders for their approval at the forthcoming Annual General Meeting.
Availability of Information
All the disclosed financial information and the outcome of the Board meeting are readily available on the company’s official website, www.marksanspharma.com, as well as on the websites of the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
Meeting Details
The Board meeting commenced at 11:55 AM and concluded at 12:45 PM on May 26, 2026.
Source: BSE
